Tandem Diabetes Care
TNDM
295 hedge funds and large institutions have $2.89B invested in Tandem Diabetes Care in 2022 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 109 increasing their positions, 102 reducing their positions, and 48 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
94% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $10.1M
1.7% more ownership
Funds ownership: 98.28% → 99.98% (+1.7%)
7% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 102
4% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 48
4% less capital invested
Capital invested by funds: $3.02B → $2.89B (-$134M)
1% less funds holding
Funds holding: 299 → 295 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$55.9M |
| 2 |
EC
Eminence Capital
New York
|
+$54M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$39.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.3M |
| 5 |
Millennium Management
New York
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$51.2M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$29.6M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$26.1M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$24.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$20.4M |
TNDM Hedge Fund Activity: Q4 2022 in Review
295 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q4 2022, worth a combined $2.89B — down 4.4% from $3.02B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new TNDM positions and 48 closed out — a net gain of 2 holders — while 109 added to existing stakes and 102 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $55.9M. The largest seller was Invesco, cutting an estimated $51.2M.
- 295 institutional investors held Tandem Diabetes Care (TNDM) as of Q4 2022, down from 299 in Q3 2022.
- Funds reported $2.89B of Tandem Diabetes Care stock for Q4 2022, down 4.4% quarter-over-quarter.
- 50 funds opened new Tandem Diabetes Care positions in Q4 2022 and 48 closed out, a net change of +2 holders.
- The largest Tandem Diabetes Care buyer in Q4 2022 was Capital International Investors, an estimated $55.9M added.
- The largest Tandem Diabetes Care seller in Q4 2022 was Invesco, an estimated $51.2M sold.
Based on aggregated 13F filings for Q4 2022.